• Orthopedics, Surgery.

    Updated: 2010-02-28 04:29:13
    Synthetic Tissue Adhesives and Sealants, Tissue Repair. Company provides a portfolio of surgical adhesives and coating products derived from synthetic biomaterials designed to enhance natural tissue repair processes while reducing post-surgical complications (e.g., biofilm formation and adhesions). The company received an NIH grant in February 2009 to be used in developing new techniques for tendon repair. The company is continuously seeking corporate partnerships and private investments to support the development of adhesive products for specific indications. Founded: 2004, Employees: 14.

  • Regenerative Medicine, Neurology.

    Updated: 2010-02-28 04:28:33
    Patient-Derived Stem Cell Therapies, Spinal Cord Injury, Multiple Sclerosis, Parkinson’s Disease. Company has developed patient-derived, adult stem cell based therapies for the treatment of neurological damage from spinal cord injury, thereby circumventing the use of generic or embryonic stem cells. Through a standard ENT procedure a patients own stem cells are harvested and then matured in a disease-specific manner to obtain a cellular population that serves to induce repair of neural damage when implanted into the site of spinal cord injury. Currently there are 250,000 patients afflicted with spinal cord injury in the US alone, with 13,000 new cases annually, a market that exceeds $20 billion. Further developments of the company’s technology are underway to treat other neurological disorders, including Multiple Sclerosis and Parkinson’s disease. The company currently seeks Series B funding to develop and commercialize its lead product for spinal

  • Regenerative Medicine, Neurology, Ophthalmology.

    Updated: 2010-02-28 04:27:19
    Stem Cell Therapies, Age Related Macular Degeneration, Parkinson’s Disease, Multiple Sclerosis. Company develops stem cell therapies for degenerative retinal and neurological diseases. Its lead product facilitates retinal pigmented epithelial cell transplantation to treat age related macular degeneration, which is the leading cause of visual impairment over the age of 55. The company is also developing neural cells to treat Parkinson’s disease and multiple sclerosis. It seeks $10 million in funding for clinical studies investigating the use of its product in Parkinson’s disease. Founded: 2005.

  • Regenerative Medicine, Neurology, Cardiology.

    Updated: 2010-02-28 04:00:29
    Tissue Engineered Composite Implants. Company is developing advanced bioengineering solutions for nerve and blood vessel regeneration to address traumatic and degenerative diseases. The company’s lead products are composite implants that combine neuronal tissue culture and biocompatible tissue engineered scaffolds. These implants are designed to cure completely transected spinal cords and facilitate recovery from massive region losses of peripheral nerves. The company has raised $3 million in financing to date, and seeks an additional financing round of $3 million. Founded: 2001, Employees: 18.

  • Bat researchers no longer flying blind

    Updated: 2010-02-25 08:52:37
    Scientists at The University of Western Ontario (Western) led an international and multi-disciplinary study that sheds new light on the way that bats echolocate. With echolocation, animals emit sounds and then listen to the reflected echoes of those sounds to form images of their surroundings in their brains........

Current Feed Items | Previous Months Items

Jan 2010 | Dec 2009 | Nov 2009 | Oct 2009 | Sep 2009 | Aug 2009